Global Patent Index - EP 1017398 A1

EP 1017398 A1 2000-07-12 - PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-KB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES

Title (en)

PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-KB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES

Title (de)

PROTEASOME INHIBITOREN, INHIBITOREN DES UBIQUITINWEGES ODER VERBINDUNGEN, DIE MIT DER DURCH DEN UBIQUITINWEG ENSTEHENDEN NF-KB AKTIVIERUNG INTERFERIEREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN UND AUTOIMMUNERKRANKUNGEN

Title (fr)

INIHIBITEURS DE PROTEASOME, INHIBITEURS DES VOIES DE L'UBIQUITINE OU AGENTS ENTRAVANT L'ACTIVATION DE NF-$g(k)B PAR LES VOIES DE l'UBIQUITINE PROTEASOME POUR TRAITER DES MALADIES INFLAMMATOIRES ET DES MALADIES AUTOIMMUNES

Publication

EP 1017398 A1 (EN)

Application

EP 98949490 A

Priority

  • US 9820065 W
  • US 6103897 P
  • US 6956297 P
  • US 7488798 P

Abstract (en)

[origin: WO9915183A1] This invention is directed to the treatment of inflammatory and autoimmune diseases by administering proteasome inhibitors, ubiquitin pathway inhibitors, agents that interfere with the activation of NF- kappa B via the ubiquitin proteasome pathway, or mixtures thereof. The invention is further directed to the treatment of inflammatory and autoimmune diseases by administering an effective combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF- kappa B via the ubiquitin proteasome pathway, or mixture thereof. Pharmaceutical compositions comprising a combination of a glucocorticoid and a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with the activation of NF- kappa B via the ubiquitin proteasome pathway, or mixture thereof are also contemplated within the scope of the invention.

IPC 1-7 (main, further and additional classification)

A61K 31/69; A61K 31/40

IPC 8 full level (invention and additional information)

A61K 45/00 (2006.01); A61K 31/16 (2006.01); A61K 31/407 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 11/06 (2006.01)

CPC (invention and additional information)

A61K 31/16 (2013.01)

Citation (search report)

See references of WO 9915183A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9915183 A1 19990401; WO 9915183 A9 19990729; AU 9580098 A 19990412; CA 2304622 A1 19990401; EP 1017398 A1 20000712; JP 2001517631 A 20011009

INPADOC legal status


2003-10-08 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20030401

2002-11-06 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20020919

2001-01-03 [RAP1] TRANSFER OF RIGHTS OF AN EP PUBLISHED APPLICATION

- Owner name: MILLENNIUM PHARMACEUTICALS, INC.

2000-07-12 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000418

2000-07-12 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE